Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Cooperative stimulation of cisplatin-mediated apoptosis by hepatitis B virus X Protein and hepatitis C virus core Protein

B형 간염 바이러스 X 단백질과 C형 간염 바이러스의 코어 단백질에 의한 cisplatin-매개성 세포 예정사의 협조적 촉진

  • Kwun, Hyun-Jin (Division of Biological Sciences, College of Natural Sciences, Pusan National University) ;
  • Jang, Kyung-Lib (Division of Biological Sciences, College of Natural Sciences, Pusan National University)
  • 권현진 (부산대학교 생명과학부) ;
  • 장경립 (부산대학교 생명과학부)
  • Published : 2007.06.25
Download PDF
⟨ Previous Next ⟩

Abstract

The co-infection with hepatitis B virus (HBV) and hepatitis C Virus (HCV) is associated with a more severe liver disease and increased frequency in the development of hepatocellular carcinoma com-pared to those with single infection. Here, we demonstrated that HBV X protein (HBx) and HCV Core cooperatively up-regulated the level of p53 in human hepatoma HepG2 cells. The elevated p53 subsequently stimulated the expression of proapoptotic Bax whereas it repressed the expression of antiapoptotic Bcl2. These effects, however, were not observed in p53-negative Hep3B cells. Consistently to their cooperative regulation of apoptotic effectors, HBx and HCV Core additively stimulated cisplatin-mediated apoptotic cell death of HepG2 but not of Hep3B cells. These results may help to explain the development of a more severe liver disease in patients co-infection with HBV and HCV as well as some contradictory results on the roles of HBx and Core in apoptosis.

B형 간염 바이러스(HBV)와 C형 간염 바이러스(HCV)에 함께 감염되면 단독 감염의 경우보다 더 심각한 간질환이 유발되고 간암으로의 발전 가능성도 높아진다. 본 연구에서는 HBV의 X단백질(HBx)과 HCV의 코어 단백질이 인간 간암세포주인 HepG2세포에서 p53의 양을 협조적으로 증가시킨다는 것을 보여 주었다. 이로 인하여 세포예정사를 촉진하는 Bax 단백질의 발현이 더 증가하는 반면에 세포예정사를 억제하는 Bcl2의 발현은 더 억제됨이 관찰되었다. 그러나 이러한 효과들은 p53-음성인 Hep3B 세포에서는 관찰되지 않았다. 나아가 HBx와 코어 단백질은 HepG2의 cisplatin-매개성 세포예정사를 협조적으로 증가시키는 반면에 Hep3B에서는 이러한 효과가 나타나지 않았다. 이러한 연구 결과들은 HBV와 HCV가 동시에 감염되었을 경우에 나타나는 임상적인 소견을 이해하고 세포예정사에 미치는 HBx와 코어 단백질의 영향에 대한 기존의 상충적인 연구결과들을 해석하는데 도움을 줄 수 있다.

Keywords

References

  1. Oren, M. 2003. Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431-442 https://doi.org/10.1038/sj.cdd.4401183
  2. Vermeulen, K., Z. N. Berneman and D. R. Van Bockstaele. 2003. Cell cycle and apoptosis. Cell Prolif. 36, 165-175 https://doi.org/10.1046/j.1365-2184.2003.00267.x
  3. Cory, S. and J. M. Adams. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656 https://doi.org/10.1038/nrc883
  4. Sionov, R. V. and Y. Haupt. 1999. The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157 https://doi.org/10.1038/sj.onc.1203130
  5. Henkler, F. and R. Koshy. 1996. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. Viral Hepat. Rev. 2, 143-159
  6. Koike, K., T. Tsutsumi, H. Fujie, Y. Shintani and M. Kyoji. 2002. Molecular mechanism of viral hepatocarcinogenesis. Oncology 62 Suppl. 1, 29-37 https://doi.org/10.1159/000048273
  7. Ahn, J. Y., E. Y. Jung, H. J. Kwun, C. W. Lee, Y. C. Sung and K. L. Jang. 2002. Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J. Gen. Virol. 83, 2765-2772 https://doi.org/10.1099/0022-1317-83-11-2765
  8. Kwun H. J. and K. L. Jang. 2003. Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J. Viral. Hepat. 10, 249-255 https://doi.org/10.1046/j.1365-2893.2003.00434.x
  9. Staib, F., S. P. Hussain, L. J. Hofseth, X. W. Wang and C. C. Harris. 2003. TP53 and liver carcinogenesis. Hum. Mutat. 21, 201-216 https://doi.org/10.1002/humu.10176
  10. Qin, L. F. and I. O. Ng. 2002. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 175, 27-38 https://doi.org/10.1016/S0304-3835(01)00720-0
  11. Ahn, J. Y., E. Y. Chung, H. J. Kwun and K. L. Jang. 2001. Transcriptional repression of $p21^{waf1}$ promoter by hepatitis B virus X protein via a p53-independent pathway. Gene 275, 163-168 https://doi.org/10.1016/S0378-1119(01)00604-7
  12. Han, H. J., E. Y. Jung, W. J. Lee and K. L. Jang. 2002. Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein. FEBS Lett. 518, 169-172 https://doi.org/10.1016/S0014-5793(02)02694-7
  13. Gorman, C. M., G. T. Merlino, M. C. Willingham, I. Pastan and B. H. Howard. 1982. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc. Natl. Acad. Sci. USA 79, 6777-6781 https://doi.org/10.1073/pnas.79.22.6777
  14. Machida, K., K. Tsukiyama-Kohara, E. Seike, S. Tone, F. Shibasaki, M. Shimizu, H. Takahashi, Y. Hayashi, N. Funata, C. Taya, H. Yonekawa and M. Kohara. 2001. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J. Biol. Chem. 276, 12140-12146 https://doi.org/10.1074/jbc.M010137200
  15. Schuster, R., W. H. Gerlich and S. Schaefer. 2000. Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene 19, 1173-1180 https://doi.org/10.1038/sj.onc.1203417
  16. Gottlob, K., M. Fulco, M. Levrero and A. Graessmann. 1998. The hepatitis B virus HBx protein inhibits caspase 3 activity. J. Biol. Chem. 273, 33347-33353 https://doi.org/10.1074/jbc.273.50.33347
  17. Benvegnu, L. and A. Alberti. 2001. Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res. 52, 199-207 https://doi.org/10.1016/S0166-3542(01)00185-1
  18. Villa, E., A. Grottola, P. Buttafoco, A. Colantoni, A. Bagni, I. Ferretti, C. Cremonini, H. Bertani and F. Manenti. 2001. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am. J. Gastroenterol. 96, 2973-2977